Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02562443




Registration number
NCT02562443
Ethics application status
Date submitted
25/09/2015
Date registered
29/09/2015
Date last updated
26/09/2022

Titles & IDs
Public title
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Scientific title
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Secondary ID [1] 0 0
2015-001476-22
Secondary ID [2] 0 0
Onconova 04-30
Universal Trial Number (UTN)
Trial acronym
INSPIRE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelodysplastic Syndrome 0 0
MDS 0 0
Refractory Anemia With Excess Blasts 0 0
RAEB 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Blood 0 0 0 0
Anaemia
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - rigosertib
Treatment: Drugs - Any approved or standard-of-care therapy
Treatment: Drugs - best supportive care (BSC)
Treatment: Drugs - best supportive care (BSC)

Experimental: rigosertib + best supportive care (BSC) -

Active comparator: Physician's Choice (PC) + best supportive care (BSC) -


Treatment: Drugs: rigosertib
Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).

Treatment: Drugs: Any approved or standard-of-care therapy
Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.

Treatment: Drugs: best supportive care (BSC)
Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.

Treatment: Drugs: best supportive care (BSC)
Patients will receive best supportive care (BSC).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival of all randomized patients and overall survival of patients scored as IPSS-R very high risk.
Timepoint [1] 0 0
Up to 30 Months
Secondary outcome [1] 0 0
Overall survival of patients with monosomy 7 chromosomal aberrations.
Timepoint [1] 0 0
Up to 30 Months
Secondary outcome [2] 0 0
Overall survival of patients with trisomy 8 chromosomal aberrations.
Timepoint [2] 0 0
Up to 30 Months
Secondary outcome [3] 0 0
Percent of patients with response according to 2006 IWG criteria.
Timepoint [3] 0 0
Up to 30 Months
Secondary outcome [4] 0 0
Scores of Quality of Life Questionnaire.
Timepoint [4] 0 0
At Baseline, at Week 4, Every 4 Weeks thereafter, and at the End-of-treatment.
Secondary outcome [5] 0 0
Percent of patients with bone marrow blast response rate according to 2006 IWG criteria.
Timepoint [5] 0 0
Up to 30 Months
Secondary outcome [6] 0 0
Percent of patients with hematologic improvement (HI) (erythroid, platelet and neutrophil responses) according to 2006 IWG criteria.
Timepoint [6] 0 0
Up to 30 Months

Eligibility
Key inclusion criteria
* MDS classified as follows:

* RAEB-1 per World Health Organization (WHO) MDS criteria (5% to <10% BM blasts)
* RAEB-2 per WHO MDS criteria (10% to <20% BM blasts)
* RAEB-t per French-American-British (FAB) classification (20% to 30% BM blasts)
* At least one cytopenia (ANC < 1800/µL or platelet count < 100,000/µL or hemoglobin [Hgb] < 10 g/dL)
* Progression (according to 2006 IWG criteria) at any time after initiation of AZA or DAC treatment or Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least six 4-week cycles of AZA or either four 4-week or four 6-week cycles of DAC administered or Relapse after initial complete or partial response or HI (according to 2006 IWG criteria)
* Duration of prior HMA therapy = 9 months and/or total = 9 cycles of prior HMA therapy in = 12 months
* Last dose of AZA or DAC within 6 months before the planned date of randomization; however, must be off these treatments for = 4 weeks before randomization
* Has failed to respond to, relapsed following, not eligible for, or opted not to participate in allogeneic stem cell transplantation
* Off all treatments for MDS (including AZA and DAC) for = 4 weeks before randomization; growth factors (G-CSF, erythropoietin and thrombopoietin) and transfusions are allowed before and during the study as clinically indicated
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Willing to adhere to protocol prohibitions and restrictions
* Patient must sign informed consent form to indicate patient's understanding study's purpose and procedures and willingness to participate. Should patient be incapable of giving consent, the patient's legally authorized representative (as defined by local regulation) must give consent. However, should patient, in any manner, choose not to participate this takes precedence and will be respected.
* Patients with 5q- syndrome should have failed to respond to or progressed on treatment with lenalidomide, where available and indicated
Minimum age
18 Years
Maximum age
81 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participation
* Eligible to receive induction chemotherapy, such as 7-10 days of cytosine arabinoside plus 2-3 days of an anthracycline, or high-dose cytarabine
* Suitable candidate to receive allogeneic stem cell transplantation; patient is eligible for study if a suitable candidate refuses to undergo an allogeneic stem cell transplant or a suitable donor cannot be found
* Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ that is unlikely to progress in two years
* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure or unstable angina pectoris
* Active infection not adequately responding to appropriate therapy
* Total bilirubin =1.5 mg/dL not related to hemolysis or Gilbert's disease
* Alanine transaminase (ALT)/aspartate transaminase (AST) =2.5 x upper limit of normal (ULN)
* Serum creatinine =2.0 mg/dL or eGFR (estimated Glomerular Filtration Rate) < 40 mL/min.
* Known active HIV, hepatitis B or hepatitis C, where active is defined as follows:

* HIV or hepatitis C - presence of viral load
* Hepatitis B - antigen positive
* Uncorrected hyponatremia (defined as serum sodium value of <130 mEq/L)
* Female patients of child-bearing potential and male patients with sexual partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the 30-day non-treatment follow-up period. Examples of acceptable contraception methods include:

* estrogen-gestagen based contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal),
* gestagen-only based contraceptives associated with inhibition of ovulation (oral, injectable, implantable),
* intra-uterine devices (IUDs),
* intra-uterine hormone-releasing systems (IUSs),
* bilateral tubal occlusion
* vasectomized partner
* sexual abstinence in accordance with an individual's lifestyle
* Female patients of child-bearing potential (pre-menopausal and not surgically sterilized) who are breast-feeding or have a positive blood beta-human chorionic gonadotropin pregnancy test at Screening
* Major surgery without full recovery or within 3 weeks before planned randomization;
* Uncontrolled hypertension
* New onset seizures (within 3 months before planned randomization) or poorly controlled seizures
* Any other concurrent investigational agent or chemotherapy, radiotherapy, immunotherapy, or corticosteroids (prednisone up to 20 mg/day or its equivalent is permitted for chronic conditions)
* Treatment with cytarabine at any dose, lenalidomide, or any other therapy targeted to the treatment of MDS (other than growth factors and other supportive care measures) within 4 weeks of planned randomization
* Investigational therapy within 4 weeks of planned randomization
* Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
* Patient previously diagnosed with AML (defined as a bone marrow or peripheral blood blast percentage of >30%).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/12/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/07/2021
Sample size
Target
Accrual to date
Final
372
Recruitment in Australia
Recruitment state(s)
QLD,TAS,VIC
Recruitment hospital [1] 0 0
Icon Cancer Care Icon South Brisbane - South Brisbane
Recruitment hospital [2] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [3] 0 0
Monash Health, Monash Medical Centre - Melbourne
Recruitment postcode(s) [1] 0 0
4101 - South Brisbane
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
3168 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Austria
State/province [18] 0 0
Linz
Country [19] 0 0
Austria
State/province [19] 0 0
Salzburg
Country [20] 0 0
Austria
State/province [20] 0 0
Vienna
Country [21] 0 0
Belgium
State/province [21] 0 0
Antwerp
Country [22] 0 0
Belgium
State/province [22] 0 0
Ghent
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Yvoir
Country [25] 0 0
Canada
State/province [25] 0 0
Manitoba
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Croatia
State/province [28] 0 0
Osijek
Country [29] 0 0
Croatia
State/province [29] 0 0
Zagreb
Country [30] 0 0
Czechia
State/province [30] 0 0
Brno
Country [31] 0 0
Czechia
State/province [31] 0 0
Hradec Kralove
Country [32] 0 0
Czechia
State/province [32] 0 0
Ostrava Poruba
Country [33] 0 0
Czechia
State/province [33] 0 0
Prague 2
Country [34] 0 0
Estonia
State/province [34] 0 0
Tallinn
Country [35] 0 0
Estonia
State/province [35] 0 0
Tartu
Country [36] 0 0
France
State/province [36] 0 0
La Roche Sur Yon Cedex 9
Country [37] 0 0
France
State/province [37] 0 0
Lille Cedex
Country [38] 0 0
France
State/province [38] 0 0
Marseille
Country [39] 0 0
France
State/province [39] 0 0
Nice Cedex 3
Country [40] 0 0
France
State/province [40] 0 0
Nimes Cedex 9
Country [41] 0 0
France
State/province [41] 0 0
Paris Cedex 10
Country [42] 0 0
France
State/province [42] 0 0
Pierre-Bénite
Country [43] 0 0
France
State/province [43] 0 0
Strasbourg Cedex
Country [44] 0 0
France
State/province [44] 0 0
Tours
Country [45] 0 0
Germany
State/province [45] 0 0
Dresden
Country [46] 0 0
Germany
State/province [46] 0 0
Düsseldorf
Country [47] 0 0
Germany
State/province [47] 0 0
Frankfurt
Country [48] 0 0
Hungary
State/province [48] 0 0
Budapest
Country [49] 0 0
Hungary
State/province [49] 0 0
Kaposvár
Country [50] 0 0
Hungary
State/province [50] 0 0
Nyíregyháza
Country [51] 0 0
Hungary
State/province [51] 0 0
Pécs
Country [52] 0 0
India
State/province [52] 0 0
Gujarat
Country [53] 0 0
India
State/province [53] 0 0
Karnataka
Country [54] 0 0
India
State/province [54] 0 0
Maharashtra
Country [55] 0 0
India
State/province [55] 0 0
Tamil Nadu
Country [56] 0 0
India
State/province [56] 0 0
West Bengal
Country [57] 0 0
Ireland
State/province [57] 0 0
Cork
Country [58] 0 0
Ireland
State/province [58] 0 0
Dublin
Country [59] 0 0
Ireland
State/province [59] 0 0
Waterford
Country [60] 0 0
Israel
State/province [60] 0 0
'Afula
Country [61] 0 0
Israel
State/province [61] 0 0
Beer Sheva
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Jerusalem
Country [64] 0 0
Israel
State/province [64] 0 0
Rehovot
Country [65] 0 0
Israel
State/province [65] 0 0
Tel Aviv
Country [66] 0 0
Israel
State/province [66] 0 0
Tel Hashomer
Country [67] 0 0
Italy
State/province [67] 0 0
Bologna
Country [68] 0 0
Italy
State/province [68] 0 0
Brescia
Country [69] 0 0
Italy
State/province [69] 0 0
Firenze
Country [70] 0 0
Italy
State/province [70] 0 0
Novara
Country [71] 0 0
Italy
State/province [71] 0 0
Pisa
Country [72] 0 0
Italy
State/province [72] 0 0
Roma
Country [73] 0 0
Italy
State/province [73] 0 0
Terni
Country [74] 0 0
Italy
State/province [74] 0 0
Torino
Country [75] 0 0
Japan
State/province [75] 0 0
Fukuoka
Country [76] 0 0
Japan
State/province [76] 0 0
Hiroshima
Country [77] 0 0
Japan
State/province [77] 0 0
Hokkaido
Country [78] 0 0
Japan
State/province [78] 0 0
Ishikawa
Country [79] 0 0
Japan
State/province [79] 0 0
Kanagawa
Country [80] 0 0
Japan
State/province [80] 0 0
Shimane
Country [81] 0 0
Japan
State/province [81] 0 0
Tokyo
Country [82] 0 0
Japan
State/province [82] 0 0
Akita
Country [83] 0 0
Japan
State/province [83] 0 0
Bunkyo-ku
Country [84] 0 0
Japan
State/province [84] 0 0
Fukuoka-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Kagoshima
Country [86] 0 0
Japan
State/province [86] 0 0
Kakamigahara
Country [87] 0 0
Japan
State/province [87] 0 0
Kawagoe
Country [88] 0 0
Japan
State/province [88] 0 0
Kobe
Country [89] 0 0
Japan
State/province [89] 0 0
Kumamoto
Country [90] 0 0
Japan
State/province [90] 0 0
Kyoto
Country [91] 0 0
Japan
State/province [91] 0 0
Nagasaki
Country [92] 0 0
Japan
State/province [92] 0 0
Nagoya-shi
Country [93] 0 0
Japan
State/province [93] 0 0
Niigata
Country [94] 0 0
Japan
State/province [94] 0 0
Oita
Country [95] 0 0
Japan
State/province [95] 0 0
Okayama
Country [96] 0 0
Japan
State/province [96] 0 0
Osakasayama-shi
Country [97] 0 0
Japan
State/province [97] 0 0
Sapporo-shi
Country [98] 0 0
Japan
State/province [98] 0 0
Sendai-shi
Country [99] 0 0
Japan
State/province [99] 0 0
Shinagawa-ku
Country [100] 0 0
Japan
State/province [100] 0 0
Shinjuku-ku
Country [101] 0 0
Japan
State/province [101] 0 0
Tochigi
Country [102] 0 0
Japan
State/province [102] 0 0
Tokushima
Country [103] 0 0
Japan
State/province [103] 0 0
Yamagata
Country [104] 0 0
Japan
State/province [104] 0 0
Yokohama-shi
Country [105] 0 0
Japan
State/province [105] 0 0
Yoshida
Country [106] 0 0
Poland
State/province [106] 0 0
Kraków
Country [107] 0 0
Poland
State/province [107] 0 0
Olsztyn
Country [108] 0 0
Poland
State/province [108] 0 0
Suwalki
Country [109] 0 0
Poland
State/province [109] 0 0
Warsaw
Country [110] 0 0
Poland
State/province [110] 0 0
Wroclaw
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Kemerovo
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Moscow
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Saint Petersburg
Country [114] 0 0
Spain
State/province [114] 0 0
Balearic Islands
Country [115] 0 0
Spain
State/province [115] 0 0
Barcelona
Country [116] 0 0
Spain
State/province [116] 0 0
Madrid
Country [117] 0 0
Spain
State/province [117] 0 0
Málaga
Country [118] 0 0
Spain
State/province [118] 0 0
Salamanca
Country [119] 0 0
Spain
State/province [119] 0 0
Valencia
Country [120] 0 0
Sweden
State/province [120] 0 0
Huddinge
Country [121] 0 0
Sweden
State/province [121] 0 0
Lund
Country [122] 0 0
Sweden
State/province [122] 0 0
Uppsala
Country [123] 0 0
Sweden
State/province [123] 0 0
Östergötland
Country [124] 0 0
Switzerland
State/province [124] 0 0
Bern
Country [125] 0 0
Switzerland
State/province [125] 0 0
Zurich
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Dorset
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Scotland
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Liverpool
Country [129] 0 0
United Kingdom
State/province [129] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Traws Pharma, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
Trial website
https://clinicaltrials.gov/study/NCT02562443
Trial related presentations / publications
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):496-508. doi: 10.1016/S1470-2045(16)00009-7. Epub 2016 Mar 9.
Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell. 2016 Apr 21;165(3):643-55. doi: 10.1016/j.cell.2016.03.045.
Navada SC, Silverman LR. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2016 Aug;16(8):805-10. doi: 10.1080/14737140.2016.1209413. Epub 2016 Jul 15.
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.
Public notes

Contacts
Principal investigator
Name 0 0
Steven M. Fruchtman, MD
Address 0 0
Traws Pharma, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02562443